Qinlock Approval History
FDA Approved: Yes (First approved May 15, 2020)
Brand name: Qinlock
Generic name: ripretinib
Dosage form: Tablets
Company: Deciphera Pharmaceuticals, Inc.
Treatment for: Gastrointestinal Stromal Tumor
Qinlock (ripretinib) is a broad-spectrum KIT and PDGFRα inhibitor for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Development History and FDA Approval Process for Qinlock
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.